REMARKS

1. Formal Matters

a. Status of the Claims

Claims 1, 2, 4-7, 9, 11, 18-24, 26, and 28-30 are pending in this application. Claims 1, 2, 4-7, 9, 11, 18-24, 26, and 28-30 are hereby canceled without prejudice to pursuing the canceled subject matter in a continuing application. Claims 31-42 are new, and claims 34-42 are withdrawn. Applicant respectfully requests entry of the amendments and remarks made herein into the file history of the instant application. Upon entry of these amendments, claims 31-42 will be pending and claims 31-33 will be under active consideration.

b. Amendments to the Claims.

Support for new claims 31-42 can be found in the application as originally filed as described in Table 1.

Claim **Location of Support** 31 paragraphs 0068-0070, Example 1 32 Example 1 33 Example 1 34 paragraphs 0047 and 0068-0070, Examples 1 and 6 35 paragraphs 0049-0052 36 Example 37 paragraph 0048, Example 1 38 paragraph 0048, Example 39 paragraph 0068 40 paragraphs 0070-0076, Examples 5-7 41 paragraphs 0070-0076, Examples 5-7 42 paragraphs 0070-0076, Examples 5-7

Table 1

2. Election/Restriction

On pages 2-11 of the Office Action, the Examiner requires restriction to one of the following inventions under 35 U.S.C. § 121 and 372:

I. Claims 1, 2, 4-7, 9, 11, and 19-22, drawn to a method for isolating or quantifying one or more T cells specific for an antigen of interest, and to a method for monitoring an autoimmune disease in a patient.

Application No. 10/524,300 Docket No. 050989.0201.01USPC

II. Claims 1, 23, and 24, drawn to a method for treating an autoimmune disease in a

patient, and drawn to a method for producing a composition for the treatment of an

autoimmune disease in a patient, said method comprising in activating T cells.

III. Claim 26, drawn to a composition for the treatment of a patient with an autoimmune

disease.

IV. Claims 28-30, drawn to a method for isolating one or more nucleic acids encoding

one more TCRs, and for determining the repertoire of said nucleic acids.

V. Claim 18, drawn to a T cell.

Applicant without traverse elects Group III, which is considered claims 31-33. Upon allowance of

these claims, Applicant will request rejoinder of withdrawn claims 34-42.

3. Conclusion

Applicant respectfully submits that the instant application is in good and proper order for

substantive examination. If, in the opinion of the Examiner, a telephone conference would expedite

prosecution of the instant application, the Examiner is encouraged to call the undersigned at the number

listed below.

Respectfully submitted,

POLSINELLI SHALTON FLANIGAN SUELTHAUS PC

Dated: February 4, 2008 On behalf of:

Teddy C. Scott, Jr., Ph.D.

Registration No. 53,573

By: /Ron Galant, Ph.D./

Ron Galant, Ph.D.

Registration No. 60,558

Customer No. 27148

POLSINELLI SHALTON FLANIGAN SUELTHAUS PC

180 N. Stetson Ave., Suite 4525

Chicago, IL 60601

312.819.1900 (main)

312.602.3955 (E-fax)

312.873.3613 (direct)

-4-